Akebia Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

Nov 04, 2025

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in two investor conferences in November: Guggenheim 2^nd Annual Healthcare Innovation Conference, taking place November 10-12, 2025 in Boston and Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025.

Guggenheim Healthcare Innovation Conference
Mr. Butler and Mr. Ostrowski will participate in a fireside chat on Monday, November 10 at 3:00 PM EST.

Jefferies Global Healthcare Conference
Mr. Butler and Mr. Ostrowski will participate in a fireside chat on Monday, November 17 at 12:00 PM GMT.

A webcast of each presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conferences.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580734443"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580734443\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580734443?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580734443","market":"hk","top_or_hot":-1,"title":"Akebia Therapeutics to Present at Upcoming Investor Conferences","media":"GlobeNewswire","content":"<html><body><p>CAMBRIDGE, Mass., Nov.  04, 2025  (GLOBE NEWSWIRE) -- <u>Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></u><sup><u>®</u></sup><u>, Inc.</u> (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in two investor conferences in November: Guggenheim 2<sup>nd</sup> Annual Healthcare Innovation Conference, taking place November 10-12, 2025 in Boston and Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025.</p> <p><strong>Guggenheim Healthcare Innovation Conference </strong><br/>Mr. Butler and Mr. Ostrowski will participate in a fireside chat on Monday, November 10 at 3:00 PM EST.</p> <p><strong>Jefferies Global Healthcare Conference</strong><br/>Mr. Butler and Mr. Ostrowski will participate in a fireside chat on Monday, November 17 at 12:00 PM GMT.</p> <p>A webcast of each presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conferences.</p> <p><strong>About Akebia Therapeutics</strong></p> <p><a href=\"https://laohu8.com/S/AKBA\">Akebia Therapeutics, Inc.</a> is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.</p> <p><strong>Akebia Therapeutics Contact</strong><br/>Mercedes Carrasco<br/>mcarrasco@akebia.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/OTBiOGE3MzAtYTVmNS00M2ZmLThiYTYtZmY3MjQwNjUyOTNhLTEwMTc5MjgtMjAyNS0xMS0wNC1lbg==/tiny/Akebia-Therapeutics-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akebia Therapeutics to Present at Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkebia Therapeutics to Present at Upcoming Investor Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2025-11-04 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>CAMBRIDGE, Mass., Nov.  04, 2025  (GLOBE NEWSWIRE) -- <u>Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></u><sup><u>®</u></sup><u>, Inc.</u> (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in two investor conferences in November: Guggenheim 2<sup>nd</sup> Annual Healthcare Innovation Conference, taking place November 10-12, 2025 in Boston and Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025.</p> <p><strong>Guggenheim Healthcare Innovation Conference </strong><br/>Mr. Butler and Mr. Ostrowski will participate in a fireside chat on Monday, November 10 at 3:00 PM EST.</p> <p><strong>Jefferies Global Healthcare Conference</strong><br/>Mr. Butler and Mr. Ostrowski will participate in a fireside chat on Monday, November 17 at 12:00 PM GMT.</p> <p>A webcast of each presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conferences.</p> <p><strong>About Akebia Therapeutics</strong></p> <p><a href=\"https://laohu8.com/S/AKBA\">Akebia Therapeutics, Inc.</a> is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.</p> <p><strong>Akebia Therapeutics Contact</strong><br/>Mercedes Carrasco<br/>mcarrasco@akebia.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/OTBiOGE3MzAtYTVmNS00M2ZmLThiYTYtZmY3MjQwNjUyOTNhLTEwMTc5MjgtMjAyNS0xMS0wNC1lbg==/tiny/Akebia-Therapeutics-Inc-.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180261/37519/en/Akebia-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.html","article_id":"2580734443","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580734443","pubTimestamp":1762261200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"CAMBRIDGE, Mass., Nov.  04, 2025  (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","XBI":"SPDR S&P Biotech ETF","BK4588":"碎股","LABU":"三倍做多标普生物-Direxion","BK4581":"高盛持仓","BK4139":"生物科技","AKBA":"Akebia Therapeutics, Inc.","XLV":"健康照护类股ETF-SPDR"},"translate_title":"Akebia Therapeutics将出席即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XLV":0.9,"XBI":0.6,"AKBA":1.5,"LABU":0.6},"content_text":"CAMBRIDGE, Mass., Nov.  04, 2025  (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in two investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference, taking place November 10-12, 2025 in Boston and Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025. Guggenheim Healthcare Innovation Conference Mr. Butler and Mr. Ostrowski will participate in a fireside chat on Monday, November 10 at 3:00 PM EST. Jefferies Global Healthcare ConferenceMr. Butler and Mr. Ostrowski will participate in a fireside chat on Monday, November 17 at 12:00 PM GMT. A webcast of each presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conferences. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release. Akebia Therapeutics ContactMercedes Carrascomcarrasco@akebia.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}